Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC By Ogkologos - September 8, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NSABP B-59/GeparDouze study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... September 23, 2025 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Skin cancer death rates in men risen dramatically in the last... July 14, 2022 Load more HOT NEWS First treatment approved in England for advanced bile duct cancer Immune cell count could determine whether chemotherapy is required in oropharyngeal... New hormone treatment for advanced prostate cancer made available in England FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial...
